PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2830-2841

  Zandi, Roza ^a   Selivanova, Galina ^d   Christensen, Camilla Laulund ^a   Gerds, Thomas Alexander ^b   Willumsen, Berthe Marie ^c   Poulsen, Hans Skovgaard ^a  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYMETHYL 2 METHOXYMETHYL AZA BICYCLO [2.2.2] OCTAN 3 ONE; ANTINEOPLASTIC AGENT; APR 246; CASPASE 3; GENOMIC DNA; MUTANT PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN NOXA; PROTEIN P53; UNCLASSIFIED DRUG; 2 HYDROXYMETHYL 2 METHOXYMETHYLAZABICYCLO(2.2.2)OCTAN 3 ONE; 2-HYDROXYMETHYL-2-METHOXYMETHYLAZABICYCLO(2.2.2)OCTAN-3-ONE; QUINUCLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL FRACTIONATION; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; UPREGULATION; ANIMAL; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECT; DRUG SCREENING; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TIME; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENES, P53; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MUTANT PROTEINS; QUINUCLIDINES; SMALL CELL LUNG CARCINOMA; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955495593     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3168     Document Type: Article

References (44)

1. Christensen CL, Zandi R, Gjetting T, Cramer F, Poulsen HS. Specifically targeted gene therapy for small-cell lung cancer. Expert Rev Anticancer Ther 2009;9:437-52.
2. Cooper S, Spiro SG. Small cell lung cancer: treatment review. Respirology 2006;11:241-8.
3. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007;12:1096-104.
4. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 2005;331: 868-80. (Pubitemid 40615518)
5. Fuster JJ, Sanz-Gonzalez SM, Moll UM, Andres V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med 2007;13:192-9. (Pubitemid 46687126)
6. Chipuk JE, Maurer U, Green DR, Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003;4:371-81. (Pubitemid 37491098)
7. Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007;26: 2243-54. (Pubitemid 46536645)
8. Rodriguez-Salas N, Palacios J, Moreno G, de Castro J, Gonzalez- Baron M, Gamallo C. Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas. Lung Cancer 2001;34:67-74. (Pubitemid 32824125)
9. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-91. (Pubitemid 24138709)
10. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al. Aberrant p53 expression predicts clinical resistance to cisplatinbased chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038-42.
11. Adachi J, Ookawa K, Shiseki M, Okazaki T, Tsuchida S, Morishita K, et al. Induction of apoptosis but not G1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma. Cell Growth Differ 1996;7:879-86. (Pubitemid 26360727)
12. Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, et al. Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res 2009;15:7719-25.
13. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282-8. (Pubitemid 34250107)
14. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002;23:2011-8. (Pubitemid 36104953)
15. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005;24:3484-91. (Pubitemid 40756249)
16. Zache N, Lambert JM, Wiman KG, Bykov VJ. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol 2008;30:411-8.
17. Phase I/II clincal study-APR-246-01 [cited 2010]. Available from: http://www.aprea.com/home/.
18. Bykov VJ, Selivanova G, Wiman KG. Small molecules that reactivate mutant p53. Eur J Cancer 2003;39:1828-34. (Pubitemid 37311177)
19. Pedersen N, Mortensen S, Sorensen SB, Pedersen MW, Rieneck K, Bovin LF, et al. Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res 2003;63:1943-53. (Pubitemid 36460862)
20. Poulsen TT, Pedersen N, Juel H, Poulsen HS. A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. Cancer Gene Ther 2008;15:563-75.
21. Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res 2005;7:R765-74.
22. de Leij L, Postmus PE, Buys CH, Elema JD, Ramaekers F, Poppema S, et al. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res 1985;45:6024-33. (Pubitemid 16224755)
23. Bulte JW, Go KG, Zuiderveen F, The TH, de Leij L. Intracerebral and subcutaneous xenografts of human SCLC in the nude rat: comparison of monoclonal antibody localization and tumor infiltrating lymphocytes. J Neurooncol 1993;16:11-8. (Pubitemid 23223537)
24. Pettengill OS, Sorenson GD, Wurster-Hill DH, Curphey TJ, Noll WW, Cate CC, et al. Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung. Cancer 1980;45:906-18. (Pubitemid 10129840)
25. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45: 2913-23.
26. Bepler G, Jaques G, Neumann K, Aumuller G, Gropp C, Havemann K. Establishment, growth properties, and morphological characteristics of permanent human small cell lung cancer cell lines. J Cancer Res Clin Oncol 1987;113:31-40. (Pubitemid 17017565)
27. Berendsen HH, de Leij L, de Vries EG, Mesander G, Mulder NH, de Jong B, et al. Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res 1988;48:6891-9. (Pubitemid 19012223)
28. Wurtzen PA, Pedersen LO, Poulsen HS, Claesson MH. Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2- restricted P53-specific CTL line. Int J Cancer 2001;93:855-61. (Pubitemid 32761693)
29. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, et al. COSMIC 2005. Br J Cancer 2006;94:318-22.
30. Hayes VM, Bleeker W, Verlind E, Timmer T, Karrenbeld A, Plukker JT, et al. Comprehensive TP53-denaturing gradient gel electrophoresis mutation detection assay also applicable to archival paraffinembedded tissue. Diagn Mol Pathol 1999;8:2-10. (Pubitemid 29300244)
31. Hensel CH, Xiang RH, Sakaguchi AY, Naylor SL. Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer. Oncogene 1991;6:1067-71. (Pubitemid 21924188)
32. Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 2008;7:699-708.
33. Nakamizo A, Amano T, Zhang W, Zhang XQ, Ramdas L, Liu TJ, et al. Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis. Neuro Oncol 2008;10:275-91.
34. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009;15:376-88.
35. Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 2010;29:1329-38.
36. Shmueli A, Oren M. Regulation of p53 by Mdm2: fate is in the numbers. Mol Cell 2004;13:4-5. (Pubitemid 38117110)
37. Muller L, Schaupp A, Walerych D, Wegele H, Buchner J. Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures. J Biol Chem 2004;279:48846-54. (Pubitemid 39625765)
38. King FW, Wawrzynow A, Hohfeld J, Zylicz M. Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. EMBO J 2001;20:6297-305. (Pubitemid 33078703)
39. Li Y, Mao Y, Brandt-Rauf PW, Williams AC, Fine RL. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol Cancer Ther 2005;4:901-9. (Pubitemid 40909072)
40. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 1995;9:2170-83.
41. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006;13:962-72.
42. Rokaeus N, Klein G, Wiman KG, Szekely L, Mattsson K. PRIMA-1 (MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins. Oncogene 2007;26:982-92.
43. Daoud SS, Wang T, Rehman A, Pommier Y. PRIMA-1 Releases the p73 bound to mutant tumor suppressor p53 in breast cancer cells. Proc Am Assoc Cancer Res 2006;47:abstr 2214.
44. Rokaeus N, Shen J, Eckhardt I, Bykov VJ, Wiman KG, Wilhelm MT. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 2010;29:6442-51.